vs
百利高（PRGO）与Primoris Services Corp（PRIM）财务数据对比。点击上方公司名可切换其他公司
Primoris Services Corp的季度营收约是百利高的1.7倍（$1.9B vs $1.1B），Primoris Services Corp净利率更高（2.8% vs -127.8%，领先130.6%），Primoris Services Corp同比增速更快（6.7% vs -2.5%），百利高自由现金流更多（$148.6M vs $121.1M），过去两年Primoris Services Corp的营收复合增速更高（14.7% vs 1.3%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
Primoris Services Corp是总部位于美国的上市专业基建与工程建设企业，核心业务覆盖天然气管道、污水管网及供水管道建设领域，2014年入选《财富》1000强榜单，在北美能源及民生基建领域拥有丰富的项目运营经验。
PRGO vs PRIM — 直观对比
营收规模更大
PRIM
是对方的1.7倍
$1.1B
营收增速更快
PRIM
高出9.2%
-2.5%
净利率更高
PRIM
高出130.6%
-127.8%
自由现金流更多
PRGO
多$27.5M
$121.1M
两年增速更快
PRIM
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.9B |
| 净利润 | $-1.4B | $51.7M |
| 毛利率 | 32.6% | 9.4% |
| 营业利润率 | -116.0% | 4.2% |
| 净利率 | -127.8% | 2.8% |
| 营收同比 | -2.5% | 6.7% |
| 净利润同比 | -3093.9% | -4.2% |
| 每股收益（稀释后） | $-10.23 | $0.94 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGOPRIM
| Q4 25 | $1.1B | $1.9B | ||
| Q3 25 | $1.0B | $2.2B | ||
| Q2 25 | $1.1B | $1.9B | ||
| Q1 25 | $1.0B | $1.6B | ||
| Q4 24 | $1.1B | $1.7B | ||
| Q3 24 | $1.1B | $1.6B | ||
| Q2 24 | $1.1B | $1.6B | ||
| Q1 24 | $1.1B | $1.4B |
净利润PRGOPRIM
| Q4 25 | $-1.4B | $51.7M | ||
| Q3 25 | $7.5M | $94.6M | ||
| Q2 25 | $-8.4M | $84.3M | ||
| Q1 25 | $-6.4M | $44.2M | ||
| Q4 24 | $-44.4M | $54.0M | ||
| Q3 24 | $-21.0M | $58.4M | ||
| Q2 24 | $-108.4M | $49.5M | ||
| Q1 24 | $2.0M | $18.9M |
毛利率PRGOPRIM
| Q4 25 | 32.6% | 9.4% | ||
| Q3 25 | 36.1% | 10.8% | ||
| Q2 25 | 34.4% | 12.3% | ||
| Q1 25 | 37.6% | 10.4% | ||
| Q4 24 | 33.9% | 10.6% | ||
| Q3 24 | 37.2% | 12.0% | ||
| Q2 24 | 37.0% | 11.9% | ||
| Q1 24 | 33.1% | 9.4% |
营业利润率PRGOPRIM
| Q4 25 | -116.0% | 4.2% | ||
| Q3 25 | 7.0% | 6.3% | ||
| Q2 25 | 4.3% | 6.7% | ||
| Q1 25 | 4.5% | 4.3% | ||
| Q4 24 | 10.0% | 5.0% | ||
| Q3 24 | 7.4% | 6.0% | ||
| Q2 24 | -2.5% | 5.5% | ||
| Q1 24 | -5.1% | 3.1% |
净利率PRGOPRIM
| Q4 25 | -127.8% | 2.8% | ||
| Q3 25 | 0.7% | 4.3% | ||
| Q2 25 | -0.8% | 4.5% | ||
| Q1 25 | -0.6% | 2.7% | ||
| Q4 24 | -3.9% | 3.1% | ||
| Q3 24 | -1.9% | 3.5% | ||
| Q2 24 | -10.2% | 3.2% | ||
| Q1 24 | 0.2% | 1.3% |
每股收益（稀释后）PRGOPRIM
| Q4 25 | $-10.23 | $0.94 | ||
| Q3 25 | $0.05 | $1.73 | ||
| Q2 25 | $-0.06 | $1.54 | ||
| Q1 25 | $-0.05 | $0.81 | ||
| Q4 24 | $-0.32 | $0.98 | ||
| Q3 24 | $-0.15 | $1.07 | ||
| Q2 24 | $-0.79 | $0.91 | ||
| Q1 24 | $0.01 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $535.5M |
| 总债务越低越好 | — | $469.9M |
| 股东权益账面价值 | $2.9B | $1.7B |
| 总资产 | $8.5B | $4.4B |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资PRGOPRIM
| Q4 25 | — | $535.5M | ||
| Q3 25 | $432.1M | $431.4M | ||
| Q2 25 | $454.2M | $390.3M | ||
| Q1 25 | $409.9M | $351.6M | ||
| Q4 24 | $558.8M | $455.8M | ||
| Q3 24 | $1.5B | $352.7M | ||
| Q2 24 | $542.8M | $207.4M | ||
| Q1 24 | $658.5M | $177.6M |
总债务PRGOPRIM
| Q4 25 | — | $469.9M | ||
| Q3 25 | — | $486.0M | ||
| Q2 25 | — | $603.1M | ||
| Q1 25 | — | $612.0M | ||
| Q4 24 | — | $734.8M | ||
| Q3 24 | — | $903.7M | ||
| Q2 24 | — | $933.0M | ||
| Q1 24 | — | $951.7M |
股东权益PRGOPRIM
| Q4 25 | $2.9B | $1.7B | ||
| Q3 25 | $4.4B | $1.6B | ||
| Q2 25 | $4.5B | $1.5B | ||
| Q1 25 | $4.4B | $1.4B | ||
| Q4 24 | $4.3B | $1.4B | ||
| Q3 24 | $4.6B | $1.4B | ||
| Q2 24 | $4.5B | $1.3B | ||
| Q1 24 | $4.7B | $1.2B |
总资产PRGOPRIM
| Q4 25 | $8.5B | $4.4B | ||
| Q3 25 | $10.1B | $4.6B | ||
| Q2 25 | $10.1B | $4.5B | ||
| Q1 25 | $9.8B | $4.2B | ||
| Q4 24 | $9.6B | $4.2B | ||
| Q3 24 | $11.2B | $4.2B | ||
| Q2 24 | $10.4B | $4.0B | ||
| Q1 24 | $10.6B | $4.0B |
负债/权益比PRGOPRIM
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.39× | ||
| Q1 25 | — | 0.42× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.67× | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | 0.76× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $142.9M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | $121.1M |
| 自由现金流率自由现金流/营收 | 13.4% | 6.5% |
| 资本支出强度资本支出/营收 | 2.4% | 1.2% |
| 现金转化率经营现金流/净利润 | — | 2.76× |
| 过去12个月自由现金流最近4个季度 | $145.1M | $340.5M |
8季度趋势，按日历期对齐
经营现金流PRGOPRIM
| Q4 25 | $175.4M | $142.9M | ||
| Q3 25 | $51.7M | $182.9M | ||
| Q2 25 | $75.9M | $78.5M | ||
| Q1 25 | $-64.5M | $66.2M | ||
| Q4 24 | $312.6M | $298.3M | ||
| Q3 24 | $42.2M | $222.5M | ||
| Q2 24 | $9.5M | $16.1M | ||
| Q1 24 | $-1.4M | $-28.5M |
自由现金流PRGOPRIM
| Q4 25 | $148.6M | $121.1M | ||
| Q3 25 | $29.8M | $148.4M | ||
| Q2 25 | $56.7M | $45.3M | ||
| Q1 25 | $-90.0M | $25.6M | ||
| Q4 24 | $274.9M | $270.0M | ||
| Q3 24 | $15.1M | $158.8M | ||
| Q2 24 | $-18.9M | $-8.1M | ||
| Q1 24 | $-26.5M | $-38.9M |
自由现金流率PRGOPRIM
| Q4 25 | 13.4% | 6.5% | ||
| Q3 25 | 2.9% | 6.8% | ||
| Q2 25 | 5.4% | 2.4% | ||
| Q1 25 | -8.6% | 1.6% | ||
| Q4 24 | 24.2% | 15.5% | ||
| Q3 24 | 1.4% | 9.6% | ||
| Q2 24 | -1.8% | -0.5% | ||
| Q1 24 | -2.4% | -2.8% |
资本支出强度PRGOPRIM
| Q4 25 | 2.4% | 1.2% | ||
| Q3 25 | 2.1% | 1.6% | ||
| Q2 25 | 1.8% | 1.8% | ||
| Q1 25 | 2.4% | 2.5% | ||
| Q4 24 | 3.3% | 1.6% | ||
| Q3 24 | 2.5% | 3.9% | ||
| Q2 24 | 2.7% | 1.5% | ||
| Q1 24 | 2.3% | 0.7% |
现金转化率PRGOPRIM
| Q4 25 | — | 2.76× | ||
| Q3 25 | 6.89× | 1.93× | ||
| Q2 25 | — | 0.93× | ||
| Q1 25 | — | 1.50× | ||
| Q4 24 | — | 5.53× | ||
| Q3 24 | — | 3.81× | ||
| Q2 24 | — | 0.32× | ||
| Q1 24 | -0.70× | -1.50× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
PRIM
| Energy Segment | $1.2B | 64% |
| Unit Price Contracts | $473.7M | 25% |
| Cost Reimbursable Contracts | $121.3M | 7% |
| Other | $74.9M | 4% |
